Amarantus to Present at Upcoming Investor Conferences
SAN FRANCISCO, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/.
Mr. Commissiong is also scheduled to present at the Aegis Capital Healthcare and Technology Conference to be held at the Wynn Las Vegas on September 10-13, 2014. His presentation will take place on Thursday, September 11th at 2:30 PM PT. Conference information may be found at http://www.meetmax.com/sched/event_25932/~public/conference_home.html?event_id=25932.
Amarantus will also be participating in the First Annual Zacks Healthcare Meetup on Monday, September 8th.
Attendees who wish to meet with management one on one may contact the conference organizers or our Investor Relations department at firstname.lastname@example.org.
Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit www.Amarantus.com, or connect with the Company on Facebook,LinkedIn, Twitter and Google+.
CONTACT: Investor/Media Contacts Aimee Boutcher Director of Investor Relations Amarantus Bioscience Holdings, Inc. 408-737-2734 x 101 email@example.com